Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours

19 Dec 2022

Abstract excerpt

Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 (NTRK2) gene, and its abnormal activation caused by NTRK2 overexpression or fusion can contribute to tumour initiation, progression, and resistance to therapeutics in multiple types of neurogenic tumours....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neuroblastoma Research and Treatments
Share to Neurofibromatosis and Schwannoma Cases
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36533776
DOI: 10.1002/cjp2.307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumoursPMID 36533776Read ↗

NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesSemantic proximity Read ↗

A review of NTRK fusions in cancerSemantic proximity Read ↗

NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy TargetSemantic proximity Read ↗

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitorsSemantic proximity Read ↗

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.Semantic proximity Read ↗

Targeting TRK: A Fast Tracked Application of Precision Oncology and Future DirectionsSemantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

Inhibiting TRK Proteins in Clinical Cancer TherapySemantic proximity Read ↗

Trk Receptor Expression and Inhibition in NeuroblastomasSemantic proximity Read ↗

Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated reviewSemantic proximity Read ↗

Testing algorithm for identification of patients with TRK fusion cancerSemantic proximity Read ↗

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.